Clinical Trial Update: Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating intensive chemotherapy with rituximab for Burkitt lymphoma and non-Hodgkin lymphoma was terminated, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Burkitt Lymphoma
• Burkitt Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Burkitt Lymphoma, Non-Hodgkins Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2013-05-23